Nanobiotix (NASDAQ:NBTX) Sees Large Volume Increase – Here’s What Happened

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) saw an uptick in trading volume on Tuesday . 34,255 shares traded hands during mid-day trading, an increase of 29% from the previous session’s volume of 26,643 shares.The stock last traded at $25.3690 and had previously closed at $23.57.

Analyst Ratings Changes

NBTX has been the subject of several research analyst reports. Wall Street Zen raised shares of Nanobiotix to a “hold” rating in a research report on Saturday, October 25th. Guggenheim boosted their price objective on Nanobiotix from $8.00 to $26.00 and gave the company a “buy” rating in a report on Friday. TD Cowen initiated coverage on Nanobiotix in a report on Friday. They set a “buy” rating on the stock. HC Wainwright reiterated a “buy” rating on shares of Nanobiotix in a report on Tuesday, November 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a research report on Thursday, January 22nd. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Nanobiotix has a consensus rating of “Moderate Buy” and an average target price of $20.00.

Nanobiotix Price Performance

The business has a fifty day moving average of $21.70 and a 200-day moving average of $17.60.

Institutional Investors Weigh In On Nanobiotix

A hedge fund recently bought a new stake in Nanobiotix stock. Optiver Holding B.V. bought a new position in Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 5,356 shares of the company’s stock, valued at approximately $101,000. Institutional investors and hedge funds own 38.81% of the company’s stock.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.